Cozy Butter · Coverage

Does Medicaid cover it where you live?

Medicaid is run by each state, so the answer changes at the state line, and five states have ended or cut back their weight coverage since January. Click your state for what your programme says and what it actually paid for.

For type 2 diabetes, Medicaid already covers these. Everywhere.

Every state Medicaid programme in the country covers GLP-1 medications for type 2 diabetes, because federal rules require it once a manufacturer signs the national rebate agreement. What each state decides separately is whether to cover the same medications for weight, and that is the difference the map below shows.

How the covered version works in practice:

  1. Your prescriber writes for a covered product. Each state keeps a preferred drug list, and one GLP-1 is usually preferred over the others. Asking which one your state prefers saves more time than any other question.
  2. The pharmacy runs a prior authorization. Most states require your prescriber to send documentation first, which typically means the diagnosis, recent A1C, and what you have already tried. This is normal and not a denial.
  3. Your managed care plan may add its own rules. If your Medicaid comes through a health plan rather than the state directly, that plan can have its own preferred list. Call the number on the card and ask for its GLP-1 criteria in writing.
  4. A denial can be appealed, and Medicaid appeals have deadlines in your favour. Ask for the reason in writing and for the fair hearing process. Many denials are about missing paperwork rather than about you.

Coverage for obstructive sleep apnea or for reducing heart risk is decided separately again, so a no for weight is not always a no.

Medicaid coverage by state

Loading the map…

Where these two numbers come from

The colour is what the programme says it covers, tracked from state notices and published summaries by GLP1Laws, with each state's own source document linked in the panel above.

The numbers are what the programme actually paid for, from the State Drug Utilization Data published by the Centers for Medicare and Medicaid Services and refreshed here every week. Read them carefully: they carry no diagnosis, so they cannot separate weight from diabetes, sleep apnea or heart risk, and they say nothing about whether the patient was an adult or a teenager. Wegovy is also approved for cardiovascular risk and Zepbound for sleep apnea, so every state pays for a few of both whatever its weight policy says. What is worth reading is the share: states that cover for weight send a third to two thirds of their GLP-1 volume to the weight-approved medications, and states that do not send under one in ten. The federal data runs one to two quarters behind, and counts under eleven prescriptions are withheld, which shows here as paid with the number held back rather than as zero.

Your state Medicaid office and your own plan are the authorities on today. This map is a place to start the call, not a substitute for it.